Abstract | BACKGROUND: METHODS: We performed a retrospective review of consecutive patients with NF1 and a diagnosis of MPNSTs between 1993 and 2003 in our referral center for NF1. Prognostic factors were evaluated by univariate analysis. RESULTS: We evaluated data for 21 patients with grade 1 (n=1), grade 2 (n=8) and grade 3 (n=12) MPNST; 16 presented localized disease and underwent surgery: margins for 6 were tumor-free (including 3 patients with amputation), 2 showed microscopic residual disease and 8 showed macroscopic residual disease. All patients received chemotherapy and 9 radiotherapy. Median time to treatment failure and overall survival were 7.8 and 17 months, respectively. Two patients were still alive at 138 and 167 months. We found no significant relationship between type of chemotherapy and time to treatment failure or overall survival. CONCLUSIONS: MPNSTs are highly aggressive in NF1. Conventional chemotherapy does not seem to reduce mortality, and its role must be questioned. Recent advances in the molecular biology of MPNSTs may provide new prognostic factors and targeted therapies.
|
Authors | Ouidad Zehou, Elizabeth Fabre, Laurent Zelek, Emilie Sbidian, Nicolas Ortonne, Eugeniu Banu, Pierre Wolkenstein, Laurence Valeyrie-Allanore |
Journal | Orphanet journal of rare diseases
(Orphanet J Rare Dis)
Vol. 8
Pg. 127
(Aug 23 2013)
ISSN: 1750-1172 [Electronic] England |
PMID | 23972085
(Publication Type: Journal Article)
|
Topics |
- Adolescent
- Adult
- Aged
- Female
- Humans
- Male
- Middle Aged
- Nerve Sheath Neoplasms
(drug therapy, etiology, mortality, surgery)
- Neurofibromatosis 1
(complications, drug therapy, mortality, surgery)
- Retrospective Studies
- Young Adult
|